Bree C. Peterson

Counsel, London



Bree Peterson is counsel in the Firm's Capital Markets group in London.

Bree's practice includes representing investment banks and issuers on a range of cross-border capital markets transactions, including SEC registered public offerings, Rule 144A/Reg S offerings, PIPE transactions, venture capital investments and other public and private financings. Bree is counsel to depositary banks in connection with implementation of American Depositary Share facilities for US offerings and other depositary receipt matters. Bree also has experience in cross-border mergers and acquisitions, Exchange Act reporting for US public companies and foreign private issuers, and complex global corporate and tax reorganizations.

Prior to joining White & Case, Bree practiced in prominent US law firms in London and Minneapolis.

Bars and Courts
Minnesota State Bar
University of St. Thomas
International Relations
University of San Diego


Advised Morgan Stanley, Goldman Sachs, Credit Suisse, VTB Capital, B of A Merrill Lynch, and Sberbank in connection with the $220 million initial public offering of Head Hunter Group PLC, a leading online recruitment platform in Russia and the CIS, on Nasdaq.

Advising placement agents, including Guggenheim Securities, Jefferies, H. C. Wainwright, Cantor Fitzgerald, Danske Bank, Oddo BHF, Baader Bank, Arctic Securities and Bryan Garnier & Co, in PIPE transactions for several publicly listed European biotech/life sciences companies, including:

  • Basilea Pharmaceutica Ltd, listed on the SIX Swiss Exchange;
  • Acacia Pharma Group plc, listed on Euronext Brussels;
  • Orphazyme A/S, listed on Nasdaq Copenhagen;
  • Valneva SE, listed on Euronext Paris;
  • Medigene AG, listed on the Frankfurt Stock Exchange;
  • BerGenBio ASA, listed on the Oslo Stock Exchange;
  • Transgene SA, list on Euronext Paris;
  • Gensight Biologics S.A., listed on Euronext Paris;
  • Onxeo S.A., listed on Euronext Paris and Nasdaq Copenhagen;
  • Zealand Pharma A/S, listed on Nasdaq Copenhagen and Nasdaq US;
  • Newron Pharmaceutical S.p.A., listed on the SIX Swiss Exchange;
  • Nicox S.A., listed on Euronext Paris; and
  • Oryzon Genomics S.A., listed on the Spanish stock exchanges.

Advising Mabion S.A., a Polish biosimilars company listed on the Warsaw Stock Exchange on its $51 million PIPE, including investments by the European Bank for Reconstruction and Development and PFR Life Science Fund sp, part of the Polish Development Fund.

Advising Numis Securities and Cowen and Company in the £80 million placing by Horizon Discovery plc to finance its acquisition of GE Healthcare Dharmacon, Inc.

Represented IHS Towers, the largest provider of mobile telecommunications infrastructure in Africa, Europe and the Middle East, on its US$500 million and US$800 million dual-tranche bond issue and on its US$500 million (equivalent) US$ and Nigerian Naira pari passu senior credit facilities agreement, which together provided IHS Towers with an aggregate US$1.8 billion (equivalent).

Advised ADES International Holding Ltd, a Dubai International Financial Centre based company and leading provider of offshore and onshore oil and gas drilling and production services in the Middle East and Africa, in connection with the issuance of $325 million 8.625% Senior Secured Notes due 2024 and on its $696 million initial public offering on the London Stock Exchange.

Advised Citi, Standard Bank and Standard Chartered as Global Coordinators in connection with the issuance of $350 million 9.25% Senior Notes due 2023 by Seplat Petroleum Development Company Plc, a Nigerian oil and gas exploration and production company.

Advising Kobalt Music Group Ltd., the largest independent music publisher in the world, on financing for its acquisition of the music publishing and neighboring rights businesses of Fintage House BV and Fintage Investments BV.

Advising Alpha Trains Group, continental Europe's largest diversified specialist train leasing company, in relation to the private placement of €250 million senior secured green floating rate notes in the USPP market.

Counsel to Kaupthing hf., an Icelandic bank, on aspects of its restructuring following its $45 billion insolvency.

Counsel to Afren plc, the Africa-focused oil exploration and production company, on aspects of its corporate restructuring involving amendments to secured facilities, bond restructurings, equity offerings and amendments of interests in its underlying oil & gas assets.

Advising Summit Therapeutics plc, an AIM-listed clinical stage drug discovery and development company, in its initial public offering on Nasdaq.*

Advising Leerink Partners, Deutsche Bank and JMP Securities as underwriters in connection with the initial public offering of ProQR Therapeutics N.V., a biopharmaceutical company engaged in development of RNA-based therapeutics, on Nasdaq.*

Advising uniQure N.V., a gene therapy company, in its initial public offering on Nasdaq.*

Advising Yandex N.V., one of the largest European internet companies and the leading search provider in Russia, in a $690 million offering of convertible senior notes (Rule 144A/Reg S).*

*Matters prior to joining White & Case